Investing.comQwen · 实盘不做把握 3/10不做原因:已被定价
北京时间·🕒 发布 08-26 22:08:36·⟳ 抓取 08-26 22:09:15 +39s·⚡ 决策 08-27 08:06:05 +9h56m·61.5 天前
Agenus在Clinical Cancer Research发表NEST二期试验更新数据：结肠癌新辅助botensilimab+balstilimab无复发
NEST试验数据此前已在学术会议报告，本次为期刊正式发表更新随访数据；AGEN股价已在13周内从约$3.5涨至$8.25（+137%），距52周高点仅6.78%，事件日股价下跌1.32%，表明市场早已充分定价botensilimab临床进展。三期ROBBIN尚未启动，不构成近期催化。
📄 原文Investing.com↗ 原文
Agenus reports no cancer recurrences in colon cancer trial
Oil prices slide amid hopes for progress in Mideast diplomacy LEXINGTON, Mass. - Agenus Inc. (NASDAQ:AGEN) reported upd…
不做 Agenus Inc（AGEN.US）
数据为已公开会议报告的期刊正式发表，非新增信息；股价13周+137%至52周高位附近，事件日下跌1.32%确认无剩余edge；三期ROBBIN尚未启动，无近期催化；小市值高波动（20日波动率7%），投机风险大
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Agenus在Clinical Cancer Research发表NEST二期更新数据（无复发、59%病理缓解率），但这是此前已公开报告的会议数据的期刊正式发表。AGEN股价13周内从100涨至237（指数化），当前$8.25距52周高$8.85仅6.78%，事件日收盘下跌1.32%，无任何正向市场反应。三期ROBBIN仅处于计划阶段。结论：信息已充分定价，无剩余edge。
🔎 新鲜度:最早出现 2026-08-26 · 扩散 low · price-in 风险 high ↗
消息传播链
- Investing.com AI生成文章报道Clinical Cancer Research发表，非一手源；标题与正文不匹配（标题写油价），说明是自动化生成的低质量报道市场反应:AGEN当日收盘$8.25，下跌1.32%，无正向反应
主要风险
- 股价波动极大（20日波动率7.04%，近5日单日涨跌幅达±9%），小市值生物科技投机性强
反向证据
- 做多前查反向 · 来源 web · 影响 invalidates
Web Search不可用，无法验证数据首次报告时间；但股价13周+137%且事件日零反应强烈暗示数据早已公开并被定价
检索:Agenus NEST trial prior data presentation ASCO ESMO 2025 2026
先例如何影响了这次决策
对本次决策的影响:Web Search不可用，无法检索历史同类先例（小市值生物科技二期数据期刊发表后的股价反应）；但基于事件日零反应和股价已大幅上涨的事实，先例缺失不改变AVOID结论
方向:无法评估
涨幅量级:无法评估
形态:无法评估
工具调用 · 历史记录,结果未知(6 种)
- fetch_decision_experience · 结果未知
- search_processed_events · 结果未知
- stock_quote · 结果未知
- web_search · 结果未知
- search_case_library · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 2,115 字
Oil prices slide amid hopes for progress in Mideast diplomacy
LEXINGTON, Mass. - Agenus Inc. (NASDAQ:AGEN) reported updated results from its Phase 2 NEST trial evaluating neoadjuvant botensilimab and balstilimab in patients with resectable colon cancer, according to a press release statement.
The results were published in Clinical Cancer Research with a data cutoff of March 31, 2026. No colorectal cancer recurrences were observed at a median follow-up of 32.2 months in NEST-1 and 23.5 months in NEST-2.
The trial enrolled 24 eligible patients with 26 resectable colorectal tumors, including 22 with mismatch repair proficient/microsatellite stable (pMMR/MSS) tumors and four with mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) tumors.
In pMMR/MSS tumors, which represent approximately 85% of early-stage colorectal cancers, the neoadjuvant treatment achieved a 59% pathologic response rate. This included 41% with a major pathologic response and 32% with a pathologic complete response.
All four dMMR/MSI-H tumors achieved a major pathologic response, including two complete responses and two with near-complete tumor regression of 98% and 99%.
Among patients with detectable circulating tumor DNA at baseline and available pre-surgical samples, 88% cleared ctDNA prior to surgery. The ctDNA remained undetectable following resection in all patients evaluated.
The study evaluated two pre-surgical treatment intervals of approximately four weeks in NEST-1 and approximately eight weeks in NEST-2. Patients in both cohorts proceeded to planned surgical resection without treatment-related delays.
No Grade 4 treatment-related adverse events, treatment-related deaths or study discontinuations were observed.
Agenus is advancing ROBBIN, a planned global randomized Phase 3 trial evaluating neoadjuvant botensilimab and balstilimab followed by standard of care versus standard of care alone in previously untreated patients with high-risk Stage II or Stage III MSS colon cancer.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
LEXINGTON, Mass. - Agenus Inc. (NASDAQ:AGEN) reported updated results from its Phase 2 NEST trial evaluating neoadjuvant botensilimab and balstilimab in patients with resectable colon cancer, according to a press release statement.
The results were published in Clinical Cancer Research with a data cutoff of March 31, 2026. No colorectal cancer recurrences were observed at a median follow-up of 32.2 months in NEST-1 and 23.5 months in NEST-2.
The trial enrolled 24 eligible patients with 26 resectable colorectal tumors, including 22 with mismatch repair proficient/microsatellite stable (pMMR/MSS) tumors and four with mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) tumors.
In pMMR/MSS tumors, which represent approximately 85% of early-stage colorectal cancers, the neoadjuvant treatment achieved a 59% pathologic response rate. This included 41% with a major pathologic response and 32% with a pathologic complete response.
All four dMMR/MSI-H tumors achieved a major pathologic response, including two complete responses and two with near-complete tumor regression of 98% and 99%.
Among patients with detectable circulating tumor DNA at baseline and available pre-surgical samples, 88% cleared ctDNA prior to surgery. The ctDNA remained undetectable following resection in all patients evaluated.
The study evaluated two pre-surgical treatment intervals of approximately four weeks in NEST-1 and approximately eight weeks in NEST-2. Patients in both cohorts proceeded to planned surgical resection without treatment-related delays.
No Grade 4 treatment-related adverse events, treatment-related deaths or study discontinuations were observed.
Agenus is advancing ROBBIN, a planned global randomized Phase 3 trial evaluating neoadjuvant botensilimab and balstilimab followed by standard of care versus standard of care alone in previously untreated patients with high-risk Stage II or Stage III MSS colon cancer.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。